Skip to content

Assessing the Synergistic Effects of Black Cohosh, Soy Isoflavones, and SDG Lignans (Soloways TM) on Menopausal Symptoms

Assessing the Synergistic Effects of Black Cohosh, Soy Isoflavones, and SDG Lignans (Soloways TM) on Menopausal Symptoms: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06328348
Enrollment
96
Registered
2024-03-25
Start date
2023-07-18
Completion date
2023-12-30
Last updated
2024-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Menopause Symptoms

Keywords

Postmenopausal women, Menopause Rating Scale, supplementation, lignans

Brief summary

This clinical trial aimed to evaluate the effectiveness of a combination of Black Cohosh, Soy Isoflavones, and SDG Lignans compared to a placebo in reducing menopausal symptoms in postmenopausal women aged 45-60 years. The study was meticulously designed to be a randomized, double-blind, parallel-group trial, ensuring rigorous scientific standards and participant confidentiality. It received ethical approval and adhered to the Declaration of Helsinki guidelines. Participants were carefully selected based on specific inclusion and exclusion criteria to maintain the study's integrity and relevance to the target population. The trial involved 96 eligible women from the Center for New Medical Technologies registry in Novosibirsk, Russia, divided into two groups through a computer-generated random sequence. One group received the active supplements, while the other received a placebo, with both groups and researchers blinded to the assignments. The supplements and placebos were produced to be indistinguishable in appearance, with dosages designed to maximize absorption and efficacy while minimizing side effects. The primary endpoint was the change in Menopause Rating Scale (MRS) scores, with secondary outcomes focusing on adverse symptoms and key hormonal changes. The study's design also included measures to ensure adherence and minimize bias, such as drug container returns and daily reminders. The involvement of S.Lab (Soloways) was limited to manufacturing the supplements, with the research conducted independently to avoid commercial influence. The sample size calculation indicated that 48 participants per group would provide adequate power to detect significant differences in menopausal symptom reduction, aiming for a high level of confidence and statistical power.

Interventions

DIETARY_SUPPLEMENTsupplementation

group receiving a course of Black Cohosh, Soy Isoflavones, and SDG Lignans

OTHERplacebo

placebo

Sponsors

Center of New Medical Technologies
CollaboratorOTHER
S.LAB (SOLOWAYS)
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
45 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* Time since menopause less than 10 years * Natural menopause confirmed * Abstainers from smoking and alcohol consumption * Normal thyroid function tests and lipid profiles * Body Mass Index (BMI) within the 18.5-30 kg/m2 range, to ensure a representative sample of the population * Recent mammography and gynecological examination (within the last year) confirming the absence of breast or reproductive system diseases

Exclusion criteria

* Contraindications to hormone therapy, including a history of suspected or diagnosed malignancy * Use of hormonal treatments or products derived from soybeans or cod liver oil within the last 12 months * Allergies to soybeans or cod liver oil * Engagement in professional athletic activities * Current use of medications that may interact with study supplements, including but not limited to sulfonamides, methotrexate, triamterene, sulfasalazine, phenytoin, anxiolytics, antidepressants, as well as daily chemicals, multivitamins, aspirin, or painkillers * Use of alternative herbal remedies for vasomotor symptoms within the past month * Participation in another investigational program involving interventions outside of routine clinical practice within the last 6 months * Presence of uncontrolled hypertension or diabetes, or a significant psychiatric condition that could interfere with study participation * History of serious cardiovascular diseases, including myocardial infarction or stroke

Design outcomes

Primary

MeasureTime frameDescription
Change in the Menopause Rating Scale (MRS) score90 daysEach symptom is rated on a scale from 0 (no complaints) to 4 (severe symptoms), leading to a total MRS score that ranges from 0 to 44

Secondary

MeasureTime frameDescription
Follicle-Stimulating Hormone (FSH) change90 days
Estradiol change90 days
Number of any adverse events90 daysany reported adverse events

Countries

Russia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 5, 2026